These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33586684)

  • 1. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
    Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
    Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
    BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.
    Morrison BM; Lachey JL; Warsing LC; Ting BL; Pullen AE; Underwood KW; Kumar R; Sako D; Grinberg A; Wong V; Colantuoni E; Seehra JS; Wagner KR
    Exp Neurol; 2009 Jun; 217(2):258-68. PubMed ID: 19285073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice.
    Fakhfakh R; Lee SJ; Tremblay JP
    Cell Transplant; 2012; 21(7):1419-30. PubMed ID: 22449443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.
    Hulmi JJ; Hentilä J; DeRuisseau KC; Oliveira BM; Papaioannou KG; Autio R; Kujala UM; Ritvos O; Kainulainen H; Korkmaz A; Atalay M
    Free Radic Biol Med; 2016 Oct; 99():308-322. PubMed ID: 27554968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activin receptor ligand trap ActRIIB:ALK4-Fc ameliorates cardiomyopathy induced by neuromuscular disease and diabetes.
    Li J; Fredericks M; Tang M; Cannell M; Joshi S; Kumar R; Andre P; Suragani RNVS
    FEBS Lett; 2022 Dec; 596(24):3145-3158. PubMed ID: 35920165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
    Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
    J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
    Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.
    Koncarevic A; Cornwall-Brady M; Pullen A; Davies M; Sako D; Liu J; Kumar R; Tomkinson K; Baker T; Umiker B; Monnell T; Grinberg AV; Liharska K; Underwood KW; Ucran JA; Howard E; Barberio J; Spaits M; Pearsall S; Seehra J; Lachey J
    Endocrinology; 2010 Sep; 151(9):4289-300. PubMed ID: 20573726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin Decoy Receptor ActRIIB:Fc Lowers FSH and Therapeutically Restores Oocyte Yield, Prevents Oocyte Chromosome Misalignments and Spindle Aberrations, and Increases Fertility in Midlife Female SAMP8 Mice.
    Bernstein LR; Mackenzie AC; Lee SJ; Chaffin CL; Merchenthaler I
    Endocrinology; 2016 Mar; 157(3):1234-47. PubMed ID: 26713784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
    Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
    Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease.
    Pearsall RS; Davies MV; Cannell M; Li J; Widrick J; Mulivor AW; Wallner S; Troy ME; Spaits M; Liharska K; Sako D; Castonguay R; Keates S; Grinberg AV; Suragani RNVS; Kumar R
    Sci Rep; 2019 Aug; 9(1):11392. PubMed ID: 31388039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
    Cunha SI; Pardali E; Thorikay M; Anderberg C; Hawinkels L; Goumans MJ; Seehra J; Heldin CH; ten Dijke P; Pietras K
    J Exp Med; 2010 Jan; 207(1):85-100. PubMed ID: 20065063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
    Amthor H; Hoogaars WM
    Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.
    O'Connell KE; Guo W; Serra C; Beck M; Wachtman L; Hoggatt A; Xia D; Pearson C; Knight H; O'Connell M; Miller AD; Westmoreland SV; Bhasin S
    FASEB J; 2015 Apr; 29(4):1165-75. PubMed ID: 25466897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model.
    Gonzalez D; Rebolledo DL; Correa LM; Court FA; Cerpa W; Lipson KE; van Zundert B; Brandan E
    Hum Mol Genet; 2018 Aug; 27(16):2913-2926. PubMed ID: 29860398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy.
    Relizani K; Mouisel E; Giannesini B; Hourdé C; Patel K; Morales Gonzalez S; Jülich K; Vignaud A; Piétri-Rouxel F; Fortin D; Garcia L; Blot S; Ritvos O; Bendahan D; Ferry A; Ventura-Clapier R; Schuelke M; Amthor H
    Mol Ther; 2014 Aug; 22(8):1423-1433. PubMed ID: 24861054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.
    Pistilli EE; Bogdanovich S; Goncalves MD; Ahima RS; Lachey J; Seehra J; Khurana T
    Am J Pathol; 2011 Mar; 178(3):1287-97. PubMed ID: 21356379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model.
    Puolakkainen T; Rummukainen P; Lehto J; Ritvos O; Hiltunen A; Säämänen AM; Kiviranta R
    PLoS One; 2017; 12(7):e0180593. PubMed ID: 28704409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.